Atea Pharmaceuticals, INC 8-K filings

Atea Pharmaceuticals announced positive Phase 3 results for its BEM/RZR regimen in treating Hepatitis C, alongside progress in its Hepatitis E drug development.

Atea Pharmaceuticals reported Q1 2026 financial results, highlighting progress in its Hepatitis C and Hepatitis E drug development programs with key Phase 3 readouts anticipated in 2026.

Atea Pharmaceuticals reported full-year 2025 financial results, provided updates on its global Phase 3 Hepatitis C Virus program, and announced the expansion of its antiviral pipeline with a new Hepatitis E Virus program.

Atea Pharmaceuticals announced its 2026 strategic priorities, including progress on its Phase 3 HCV program and initiation of a Phase 1 HEV study, alongside a strong cash position of $301.8 million.

Atea Pharmaceuticals announced its third quarter 2025 financial results, highlighted by on-track patient enrollment in its global Phase 3 Hepatitis C Virus program and the expansion into a new Hepatitis E Virus development program.

Atea Pharmaceuticals reported Q2 2025 financial results and provided a business update, highlighting significant progress in its global Phase 3 program for HCV treatment and a share repurchase initiative.

Atea Pharmaceuticals, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the election of three Class II directors, ratification of KPMG LLP as auditor, and advisory approval of executive compensation.

Atea Pharmaceuticals reports first quarter 2025 financial results and provides a business update on its Phase 3 clinical trials for HCV treatment.

Atea Pharmaceuticals appoints Howard H. Berman to its Board of Directors, initiates a $25 million share repurchase program, and enters into an agreement with activist investors Bradley L. Radoff and Michael Torok.

Driver Opportunity Partners III withdraws its nomination of J. Abbott R. Cooper for election to Atea Pharmaceuticals' Board of Directors at the 2025 Annual Meeting of Stockholders.

Atea Pharmaceuticals confirms it has received notice from shareholders Bradley L. Radoff and Driver Opportunity Partners III LP intending to nominate director candidates for election at the 2025 Annual Meeting of Stockholders.

Atea Pharmaceuticals reports successful FDA meeting for its HCV program and plans to initiate Phase 3 trials, alongside cost-cutting measures and a new board appointment.

Atea Pharmaceuticals has elected Arthur Kirsch, a seasoned healthcare investment banking professional, to its Board of Directors, effective February 20, 2025.

Atea Pharmaceuticals outlines its 2025 strategic priorities, including the initiation of a global Phase 3 program for its bemnifosbuvir and ruzasvir regimen targeting the $3 billion HCV market.

Atea Pharmaceuticals reported its third quarter 2024 financial results and provided an update on its Hepatitis C Virus (HCV) program, including upcoming data presentations and plans for a Phase 3 trial.

Atea Pharmaceuticals reported its second quarter 2024 financial results and provided updates on its COVID-19 and Hepatitis C Virus (HCV) clinical programs, including the completion of enrollment in key trials.

Atea Pharmaceuticals successfully held its 2024 Annual Meeting, electing two Class I directors and approving the ratification of the company's independent auditor and executive compensation.

Atea Pharmaceuticals reported its first quarter 2024 financial results and provided updates on its COVID-19 and Hepatitis C clinical trials, including the completion of enrollment for the Phase 3 SUNRISE-3 trial.

Atea Pharmaceuticals reported positive final results from its Phase 2 HCV study lead-in cohort and provided an update on its Phase 3 COVID-19 trial, SUNRISE-3.